��������

Vijayapal “Vijay” Reddy, PhD has nearly 30 years of experience in the global drug discovery and development. His industry experience includes over 22 years with Eli Lilly and Company. Since then, as a Director at Vipra, LLC, he provides strategic scientific input and direction in several disease areas including cancer. During his tenure at Lilly, he was a critical contributor in delivering nonclinical toxicology packages to support first in human studies (INDs) for many drug candidates and successfully submitted two NDAs (Evista, Alimta) and two BLAs (Cyramza and Lartruvo).

Vijay received his PhD from Utah State University, his MS from the University of Mississippi Medical Center, and his DVM (BVSc) from the A.P. Agricultural University, India. He completed a postdoctoral fellowship at the University of Nebraska Medical Center.